News Column

NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights

August 4, 2014

By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), reported business highlights for the quarter ended June 30, 2014 (see also NeuroMetrix, Inc.).

The Company operates in two primary markets - wearable medical technology and point-of-care tests. The Company's SENSUS device is a wearable transcutaneous electrical nerve stimulator indicated for management of chronic pain, and is the only such device cleared by the FDA for use during sleep. It is lightweight and can be worn during the day while remaining active, and at night while sleeping. SENSUS is beneficial in treating various forms of chronic pain, particularly neuropathic pain such as painful diabetic neuropathy, which affects about one quarter of people with diabetes. The Company's point-of-care neuropathy test, DPNCheck, addresses an unmet medical need for accurate and cost-effective screening, diagnosing and monitoring of peripheral neuropathies such as diabetic peripheral neuropathy. DPNCheck has found growing acceptance among Medicare Advantage plans where it is used in the clinically and financially important risk adjustment process. DPNCheck is being introduced into the Japan and China markets through a partnership with Omron Healthcare.

Keywords for this news article include: Legal Issues, NeuroMetrix Inc, Investment and Finance.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Pain & Central Nervous System Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters